NCCN Guidelines for HR+ HER2 Metastatic Breast Cancer

1 Views
administrator
administrator
07/03/23

Debu Tripathy, MD, and Hatem Soliman, MD, reflect on the NCCN guideline criteria and patient factors that play into decision making for frontline therapy in hormone receptor–positive metastatic breast cancer.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next